NCT05204264

Brief Summary

Background: There is a paucity of randomized clinical trials which address the relationship between training in mindfulness and neuropsychological outcomes. Also, how psychotherapeutic interventions were delivered before and during the COVID-19 pandemic and its possible differential results need more scientific attention. Aims: To compare the effectiveness of an intervention based on the Acceptance and Commitment Therapy (ACT) versus a Mindfulness-based Emotional Regulation (MER) intervention among adult patients with anxiety disorders. Methods: This randomized, single-blind, clinical trial is being conducted in a community Mental Health Unit (Colmenar Viejo, Madrid) in Spain. Potential outpatients will be over 18 years (until 75 years) with some type of specific or unspecified anxiety disorder. They will be assessed for inclusion/exclusion criteria and randomized according to the score on the Acceptance and Action Questionnaire-II (used as a blocking factor). One of the interventions was adapted from the Acceptance and Commitment Therapy (ACT) for anxiety disorders and MER was based on the Mindfulness-Based Stress Reduction program. Each intervention has been designed to be weekly, during 8 weeks, guided by two Clinical Psychology residents. Interventions have been delivered face-to-face before the COVID-19 pandemic, or via online currently. A 2x3 mixed-factorial ANOVA (intervention type x pre-treatment, post-treatment and 6-month follow-up) will be conducted, with Sidak-correction post hoc tests. The primary measures are the TMT score (A and B forms), Stroop test, Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (Forward, Backward and Sequencing subtests), Acceptance and Action Questionnaire-II, and Anxiety Sensitivity Index-3 (ASI-3). Secondary measures are the Five Facets Mindfulness Questionnaire (FFMQ), Toronto Alexithymia Scale 20-item (TAS-20), Reflective Functioning Questionnaire (RFQ-8), Hospital Anxiety and Depression Scale (HADS), and the World Health Organization's Quality of Life Questionnaire (WHOQOL-BREF). Norms based on the Spanish general population will be used. Results: This clinical trial started in February 2019 and it is expected to end in September 2023. The minimum sample size required is 128 participants (64 each intervention) to achieve medium effect sizes on primary outcomes (alfa = .05 and beta = .20). So far, 107 adult patients with anxiety disorders participated (64 participants in face-to-face interventions before the COVID-19 pandemic; and 43 participants via online, during the pandemic). Conclusions: This is the first study to compare two mindfulness-based interventions on several neurocognitive functions and other psychological domains among adult patients with anxiety disorders.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
128

participants targeted

Target at P50-P75 for not_applicable anxiety

Timeline
Completed

Started Feb 2019

Longer than P75 for not_applicable anxiety

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 18, 2019

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

January 11, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 24, 2022

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2023

Completed
Last Updated

February 7, 2022

Status Verified

January 1, 2022

Enrollment Period

4.5 years

First QC Date

January 11, 2022

Last Update Submit

January 24, 2022

Conditions

Keywords

Acceptance and Commitment TherapyMindfulness-based Emotional RegulationRandomized clinical trialNeuropsychology

Outcome Measures

Primary Outcomes (15)

  • Trail Making Test (TMT)

    It evaluates selective/alternative visual attention by the time of execution (seconds)

    Baseline

  • Trail Making Test (TMT)

    It evaluates selective/alternative visual attention by the time of execution (seconds)

    2 months

  • Trail Making Test (TMT)

    It evaluates selective/alternative visual attention by the time of execution (seconds)

    8 months

  • Stroop Color-Word Interference Test

    It measures processing speed and visual inhibitory control by the total number of items achieved

    Baseline

  • Stroop Color-Word Interference Test

    It measures processing speed and visual inhibitory control by the total number of items achieved

    2 months

  • Stroop Color-Word Interference Test

    It measures processing speed and visual inhibitory control by the total number of items achieved

    8 months

  • Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (WAIS-IV): Forward, Backward and Sequencing subtests

    It evaluates span of immediate recall and verbal working memory by the total number of items achieved and the maximum number of remembered elements

    Baseline

  • Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (WAIS-IV): Forward, Backward and Sequencing subtests

    It evaluates span of immediate recall and verbal working memory by the total number of items achieved and the maximum number of remembered elements

    2 months

  • Digit span subtests from the Wechsler Adult Intelligence Scale, version IV (WAIS-IV): Forward, Backward and Sequencing subtests

    It evaluates span of immediate recall and verbal working memory by the total number of items achieved and the maximum number of remembered elements

    8 months

  • The Acceptance and Action Questionnaire-II (AAQ-II)

    It evaluates experiential avoidance and psychological inflexibility. It is a 7-item self-report instrument, rated on a 7-point Likert scale, with a total scale score ranging from 7 to 49. Higher scores indicate higher levels of experiential avoidance and psychological inflexibility

    Baseline

  • The Acceptance and Action Questionnaire-II (AAQ-II)

    It evaluates experiential avoidance and psychological inflexibility. It is a 7-item self-report instrument, rated on a 7-point Likert scale, with a total scale score ranging from 7 to 49. Higher scores indicate higher levels of experiential avoidance and psychological inflexibility

    2 months

  • The Acceptance and Action Questionnaire-II (AAQ-II)

    It evaluates experiential avoidance and psychological inflexibility. It is a 7-item self-report instrument, rated on a 7-point Likert scale, with a total scale score ranging from 7 to 49. Higher scores indicate higher levels of experiential avoidance and psychological inflexibility

    8 months

  • The Anxiety Sensitivity Index-3 (ASI-3)

    It measures concerns associated with possible negative consequences of anxiety-related symptoms in three dimensions (physical, cognitive and social). It is an 18-item self-report, rated on a 5-point Likert scale, with a total scale score (ranging from 0 to 72) and three 6-item subscales (Physical, Cognitive and Social Concerns, ranging from 0 to 24 points each). Higher scores indicate higher anxiety sensitivity

    Baseline

  • The Anxiety Sensitivity Index-3 (ASI-3)

    It measures concerns associated with possible negative consequences of anxiety-related symptoms in three dimensions (physical, cognitive and social). It is an 18-item self-report, rated on a 5-point Likert scale, with a total scale score (ranging from 0 to 72) and three 6-item subscales (Physical, Cognitive and Social Concerns, ranging from 0 to 24 points each). Higher scores indicate higher anxiety sensitivity

    2 months

  • The Anxiety Sensitivity Index-3 (ASI-3)

    It measures concerns associated with possible negative consequences of anxiety-related symptoms in three dimensions (physical, cognitive and social). It is an 18-item self-report, rated on a 5-point Likert scale, with a total scale score (ranging from 0 to 72) and three 6-item subscales (Physical, Cognitive and Social Concerns, ranging from 0 to 24 points each). Higher scores indicate higher anxiety sensitivity

    8 months

Secondary Outcomes (15)

  • The Five Facets of Mindfulness Questionnaire (FFMQ)

    Baseline

  • The Five Facets of Mindfulness Questionnaire (FFMQ)

    2 months

  • The Five Facets of Mindfulness Questionnaire (FFMQ)

    8 months

  • The Toronto Alexithymia Scale 20-item (TAS-20)

    Baseline

  • The Toronto Alexithymia Scale 20-item (TAS-20)

    2 months

  • +10 more secondary outcomes

Study Arms (2)

Acceptance and Commitment Therapy (ACT)

EXPERIMENTAL

Intervention based on Acceptance and Commitment Therapy that promotes the acceptance and defusion of unwanted internal experiences and commitment to values of the personal life project.

Behavioral: Acceptance and Commitment Therapy (ACT)

Mindfulness-based Emotional Regulation (MER)

EXPERIMENTAL

Intervention inspired in the Mindfulness-Based Stress Reduction program that fosters the development of a behavioral pattern made up of conscious responses in order to decrease reactivity to stressors.

Behavioral: Mindfulness-based Emotional Regulation (MER)

Interventions

This intervention uses techniques based on mindfulness, metaphors and exposition exercises both in imagination and in real contexts.

Acceptance and Commitment Therapy (ACT)

This intervention includes both formal practices of body scan meditation, standing / sitting Hatha yoga, meditations focused on the breath or other objects of attention, exercises of benevolence or kindness with affection (loving-kindness); as well as informal mindfulness practices in activities of daily living.

Mindfulness-based Emotional Regulation (MER)

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Spanish as mother tongue or a very high level in Spanish to understand the patient information sheet, the informed consent, as well as being able to follow the group intervention sessions and the homework.
  • Diagnosis of an anxiety disorder, avoidant personality disorder, adjustment disorders with anxious/anxious-depressive symptomatology, as well as unspecified anxiety disorders.

You may not qualify if:

  • Continuing individual psychotherapeutic treatment from the beginning of the group intervention until the end of it.
  • Other diagnoses of severe mental disorder; cluster A or B personality disorders; and/or substance use disorder in the past 6 months.
  • Diagnosis of intellectual disability, mild cognitive impairment or dementia.
  • Changes in psychopharmacological treatment (in active ingredient or doses) in the month before each intervention.
  • Diagnosis of uncontrolled or non-stabilized organic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro de Salud Mental de Colmenar Viejo Sur

Colmenar Viejo, Madrid, 28770, Spain

RECRUITING

Related Links

MeSH Terms

Conditions

Anxiety Disorders

Interventions

Acceptance and Commitment Therapy

Condition Hierarchy (Ancestors)

Mental Disorders

Intervention Hierarchy (Ancestors)

Cognitive Behavioral TherapyBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Eduardo Fernández-Jiménez, PhD

    Hospital Universitario La Paz

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Eduardo Fernández-Jiménez, PhD

CONTACT

Ana Hospital-Moreno, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participants will be randomized according to the score on the Acceptance and Action Questionnaire-II (blocking factor) without knowing the treatment they were allocated to.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 11, 2022

First Posted

January 24, 2022

Study Start

February 18, 2019

Primary Completion

September 1, 2023

Study Completion

September 1, 2023

Last Updated

February 7, 2022

Record last verified: 2022-01

Locations